DE602004014187D1 - Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person - Google Patents

Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person

Info

Publication number
DE602004014187D1
DE602004014187D1 DE602004014187T DE602004014187T DE602004014187D1 DE 602004014187 D1 DE602004014187 D1 DE 602004014187D1 DE 602004014187 T DE602004014187 T DE 602004014187T DE 602004014187 T DE602004014187 T DE 602004014187T DE 602004014187 D1 DE602004014187 D1 DE 602004014187D1
Authority
DE
Germany
Prior art keywords
person
cell
urocanic acid
cytoplasmas
introduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004014187T
Other languages
English (en)
Inventor
Lasse Leino
Jarmo Laihia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocis Pharma Oy
Original Assignee
Biocis Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29763491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004014187(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocis Pharma Oy filed Critical Biocis Pharma Oy
Publication of DE602004014187D1 publication Critical patent/DE602004014187D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE602004014187T 2003-12-09 2004-11-26 Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person Active DE602004014187D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus
PCT/FI2004/000717 WO2005056007A1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person

Publications (1)

Publication Number Publication Date
DE602004014187D1 true DE602004014187D1 (de) 2008-07-10

Family

ID=29763491

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014187T Active DE602004014187D1 (de) 2003-12-09 2004-11-26 Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person

Country Status (17)

Country Link
US (2) US20060189691A1 (de)
EP (1) EP1691805B1 (de)
JP (1) JP4825680B2 (de)
CN (1) CN1889950B (de)
AT (1) ATE396723T1 (de)
AU (1) AU2004296570B2 (de)
CA (1) CA2544720C (de)
CY (1) CY1108163T1 (de)
DE (1) DE602004014187D1 (de)
DK (1) DK1691805T3 (de)
ES (1) ES2303113T3 (de)
FI (1) FI20031793A0 (de)
PL (1) PL1691805T3 (de)
PT (1) PT1691805E (de)
SI (1) SI1691805T1 (de)
WO (1) WO2005056007A1 (de)
ZA (1) ZA200602940B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126058T1 (de) * 1990-06-29 1995-08-15 Bode Chemie Gmbh & Co Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsäure.
US5455036A (en) * 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
DE4122497C2 (de) 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
WO1997047355A1 (en) * 1996-06-12 1997-12-18 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
DE19638064C2 (de) * 1996-09-18 1998-08-20 Voith Turbo Kg Verfahren zur Steuerung von Schaltvorgängen bei einem Fahrzeuggetriebe
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
JP2003530850A (ja) * 2000-04-14 2003-10-21 ユニバーシティー オブ サウス カロライナ リサーチ ファウンデーション 生物活性ヒスチジンアンモニアリアーゼのクローニング、過剰発現および治療用途
US6582734B1 (en) 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Also Published As

Publication number Publication date
CA2544720A1 (en) 2005-06-23
US20060189692A1 (en) 2006-08-24
CN1889950A (zh) 2007-01-03
EP1691805A1 (de) 2006-08-23
CN1889950B (zh) 2011-02-09
AU2004296570A1 (en) 2005-06-23
CA2544720C (en) 2012-01-03
US20060189691A1 (en) 2006-08-24
ZA200602940B (en) 2007-07-25
ATE396723T1 (de) 2008-06-15
CY1108163T1 (el) 2014-02-12
JP4825680B2 (ja) 2011-11-30
PL1691805T3 (pl) 2008-11-28
AU2004296570B2 (en) 2011-01-06
FI20031793A0 (fi) 2003-12-09
WO2005056007A1 (en) 2005-06-23
PT1691805E (pt) 2008-06-12
EP1691805B1 (de) 2008-05-28
ES2303113T3 (es) 2008-08-01
DK1691805T3 (da) 2008-10-06
JP2007513927A (ja) 2007-05-31
SI1691805T1 (sl) 2008-08-31
US8338475B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
DK1161248T3 (da) Farmaceutisk sammensætning indeholdende en nitratkilde og et forsurende middel til behandling af åbne sår og forbrændinger
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE495187T1 (de) Dalda-analoge und ihre verwendung
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
DE60326370D1 (de) Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE602004014187D1 (de) Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
ATE428709T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
SE9802207D0 (sv) Novel compounds
TW200512193A (en) Pyridinyl carbamates

Legal Events

Date Code Title Description
8364 No opposition during term of opposition